Evidence map›Paper›PMID 41029497›Full record

ArticleBMC cancer2025

DHX9 as a prognostic biomarker and its biological roles in acute myeloid leukemia.

Yacen Xiong, Yan Chen, Huixin Luo, Minhui Shi, Chong Wang, Xueyang Hu, Huaiping Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yacen XiongDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China.
Yan ChenDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China.
Huixin LuoDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China.
Minhui ShiDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China.
Chong WangDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China.
Xueyang HuDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China.
Huaiping ZhuDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China. huaipingzhu@ustc.edu.cn.

Funding

National Natural Science Foundation of China 31870897
6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) is a highly malignant hematopoietic disease, with low remission and high relapse rates, and there is currently no effective treatment except for acute promyelocytic leukemia. DExH-Box Helicase 9, a member of the DExD/H-box family of helicases, is highly expressed in some solid tumors and associated with poor prognosis. However, its role in AML has not been reported. This study aimed to investigate the clinical significance and biological roles of DHX9 in AML.

methodsSpecific gene primers and TaqMan probes were prepared to construct absolute quantitative methods for DHX9. Receiver operating characteristic curves were constructed to evaluate the diagnostic and prognostic value of DHX9. Series of shRNA-mediated DHX9 knockdown experiments to assess the functional roles of DHX9 such as proliferation, cell cycle, apoptosis and differentiation ability. In addition, bioinformatic analysis was used to find out which potential pathways DHX9 participated in.

resultsA detection method for DHX9 was successfully established. DHX9 was highly expressed in the AML patients with aberrant myeloid blasts. Significant differences were found among patients with different risk levels, with high levels of DHX9 related to a poor prognosis. shRNA-mediated DHX9 knockdown significantly inhibited the proliferation and cell cycle, and induced apoptosis and differentiation in THP-1 and MOLM-13 cells. Further bioinformatic analysis showed that DHX9 expression was significantly associated with metabolism pathways, suggesting that DHX9 may be involved in the metabolic reprogramming of AML blasts.

conclusionsOur study discovers that DHX9 promotes AML development and may serve as a biomarker for AML, holding a better prospect for clinical application.

Indexed as

Biomarkers, TumorDEAD-box RNA HelicasesLeukemia, Myeloid, AcuteAdultAgedApoptosisCell CycleCell DifferentiationCell Line, TumorCell ProliferationFemaleGene Knockdown TechniquesHumansMaleMiddle AgedNeoplasm ProteinsBiomarkers, TumorDEAD-box RNA HelicasesDHX9 protein, humanNeoplasm ProteinsAcute myeloid leukemiaApoptosisBiomarkerDExH-Box helicase 9Proliferation

Identifiers

PMID41029497
PMCPMC12481950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.